Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBUNASDAQ:GLSINASDAQ:GRCENASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.34+4.7%$0.97$0.66▼$3.00$119.05M2.441.34 million shs2.07 million shsGLSIGreenwich LifeSciences$8.90-0.2%$9.59$8.06▼$18.15$119.25M1.6946,134 shs33,040 shsGRCEGrace Therapeutics$3.00-2.3%$2.74$1.75▼$4.97$31.13M0.8937,148 shs95,213 shsRAPTRapt Therapeutics$7.43+0.1%$7.46$5.67▼$30.60$122.70M-0.11161,581 shs152,905 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences+4.69%+20.72%+32.02%+28.85%-18.29%GLSIGreenwich LifeSciences-0.22%-3.26%-8.53%-19.89%-44.27%GRCEGrace Therapeutics-2.28%+5.63%+2.74%+17.65%+299,999,900.00%RAPTRapt Therapeutics+0.13%-10.70%+4.59%-29.10%-70.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBUCaribou Biosciences2.5227 of 5 stars3.53.00.00.01.81.70.6GLSIGreenwich LifeSciences1.9789 of 5 stars3.51.00.00.00.03.30.0GRCEGrace Therapeutics1.6467 of 5 stars3.50.00.00.00.00.81.3RAPTRapt Therapeutics3.8985 of 5 stars3.21.00.04.22.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 3.00Buy$8.50534.33% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00338.20% UpsideGRCEGrace Therapeutics 3.00Buy$12.00300.00% UpsideRAPTRapt Therapeutics 2.33Hold$24.00223.01% UpsideCurrent Analyst Ratings BreakdownLatest GRCE, RAPT, GLSI, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025RAPTRapt TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.005/22/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$48.005/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$9.99M12.47N/AN/A$2.79 per share0.48GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AGRCEGrace TherapeuticsN/AN/AN/AN/A$6.57 per shareN/ARAPTRapt Therapeutics$1.53M80.32N/AN/A$11.51 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)GLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)GRCEGrace Therapeutics-$12.85M-$1.16N/AN/AN/AN/A-20.10%-17.10%N/ARAPTRapt Therapeutics-$129.87M-$2.40N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)Latest GRCE, RAPT, GLSI, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/8/2025Q1 2025CRBUCaribou Biosciences-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million5/8/2025Q1 2025RAPTRapt Therapeutics-$2.48-$0.64+$1.84-$0.08N/AN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A7.637.63GLSIGreenwich LifeSciencesN/A1.911.91GRCEGrace TherapeuticsN/A6.066.06RAPTRapt TherapeuticsN/A21.1121.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%GLSIGreenwich LifeSciences4.16%GRCEGrace Therapeutics6.08%RAPTRapt Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences8.28%GLSIGreenwich LifeSciences51.67%GRCEGrace Therapeutics13.51%RAPTRapt Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10093.00 million85.30 millionOptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionableGRCEGrace TherapeuticsN/A10.14 million8.77 millionN/ARAPTRapt Therapeutics8016.54 million16.15 millionOptionableGRCE, RAPT, GLSI, and CRBU HeadlinesRecent News About These CompaniesRapt Therapeutics (NASDAQ:RAPT) Shares Gap Down - Time to Sell?June 18 at 1:41 PM | marketbeat.comWall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should KnowJune 18 at 10:55 AM | zacks.comRAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025June 15, 2025 | nasdaq.comRAPT Therapeutics, Inc. Announces 1-for-8 Reverse Stock Split Effective June 16, 2025June 15, 2025 | nasdaq.comRAPT Therapeutics (NASDAQ:RAPT) Shares Scheduled to Reverse Split on Tuesday, June 17thJune 13, 2025 | marketbeat.comRAPT Therapeutics, Inc.: RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock SplitJune 13, 2025 | finanznachrichten.deRAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock SplitJune 13, 2025 | globenewswire.comTwo Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)June 12, 2025 | marketbeat.comClear Street initiates Rapt Therapeutics stock with buy ratingJune 7, 2025 | uk.investing.comRapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash PositionJune 6, 2025 | msn.comRapt Therapeutics cuts staff for 2nd time in under a year, continuing fallout from FDA holdJune 4, 2025 | fiercebiotech.comRAPT Therapeutics to Participate in Upcoming Investor ConferencesJune 4, 2025 | globenewswire.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from BrokeragesJune 3, 2025 | marketbeat.comShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 39.9%June 2, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for RAPT Q2 Earnings?May 27, 2025 | marketbeat.com12 Health Care Stocks Moving In Friday's Intraday SessionMay 25, 2025 | benzinga.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Hold" at Wall Street ZenMay 24, 2025 | marketbeat.comUBS Group Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock PriceMay 24, 2025 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Earns Buy Rating from HC WainwrightMay 24, 2025 | marketbeat.comRapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should KnowMay 16, 2025 | zacks.comRAPT Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRCE, RAPT, GLSI, and CRBU Company DescriptionsCaribou Biosciences NASDAQ:CRBU$1.34 +0.06 (+4.69%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.38 +0.04 (+2.99%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Greenwich LifeSciences NASDAQ:GLSI$8.90 -0.02 (-0.22%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$8.88 -0.03 (-0.28%) As of 06/20/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Grace Therapeutics NASDAQ:GRCE$3.00 -0.07 (-2.28%) As of 06/20/2025 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Rapt Therapeutics NASDAQ:RAPT$7.43 +0.01 (+0.13%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.64 +0.22 (+2.89%) As of 06/20/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
